A61P 43 - Drugs for specific purposes, not provided for in groups

Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
11/2002
11/14/2002	WO2002089792A1 Sulfonamides
11/14/2002	WO2002089791A2 Acne treatment with lipooxigenase inhibitors
11/14/2002	WO2002089789A1 Trimethyl lock based tetrapartate prodrugs
11/14/2002	WO2002089787A1 Potentiation of therapeutic effects of fatty acids
11/14/2002	WO2002089785A1 Sulfonamides
11/14/2002	WO2002089784A1 Novel sphingolipid synthesis inhibitor
11/14/2002	WO2002089783A1 Substituted cyclohexan-1,4-diamine derivatives with constipating and peripheral analgesic properties
11/14/2002	WO2002089779A2 Combined preparation for the prophylaxis and/or therapy of nerve cell and/or glia cell damage using a novel method of treatment
11/14/2002	WO2002089778A2 Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
11/14/2002	WO2002089776A1 Nanoparticles made of protein with coupled apolipoprotein e for penetration of the blood-brain barrier and methods for the production thereof
11/14/2002	WO2002089775A1 Coated granules based on angiotensin-converting enzyme inhibitor
11/14/2002	WO2002089771A1 Liposomes
11/14/2002	WO2002089749A2 Arylsulfonamide ethers, and methods of use thereof
11/14/2002	WO2002089743A2 Use of compositions for treating rosacea
11/14/2002	WO2002089740A2 Sulfonamides
11/14/2002	WO2002089729A2 Fused heterocyclic compounds
11/14/2002	WO2002076990A8 Thiazolopyrimidine derivatives and use thereof as antagonists of the cx3 cr1 receptor
11/14/2002	WO2002076476A3 Prodrugs of anticancer agents employing substituted aromatic acids
11/14/2002	WO2002074764A3 Piperazine derivatives and their use as 5-ht1b ligands
11/14/2002	WO2002074326A3 Urocortin-iii and uses thereof
11/14/2002	WO2002072577A3 Azacycloalkyl substituted acetic acid derivatives for use as mmp inhibitors.
11/14/2002	WO2002072089A3 Use of thiolutin dioxide and its derivatives in the manufacture of a medicament for the treatment of cns disorders and a process for the preparation thereof
11/14/2002	WO2002067764A3 Alzheimer's disease diagnosis based on mitogen-activated protein kinase phosphorylation
11/14/2002	WO2002064616A3 Agonists and antagonists of sphingosine-1-phosphate receptors
11/14/2002	WO2002060339A3 Ophthalmic compositions for treating ocular hypertension
11/14/2002	WO2002055152A8 Composition for inducing islet neogenesis, containing gastrin/cck receptor ligands and egf receptor ligands
11/14/2002	WO2002055014A3 Therapeutic chroman compounds
11/14/2002	WO2002055012A3 Therapeutic heterocyclic compounds
11/14/2002	WO2002053167A3 Pharmaceutical combination for the treatment of tissue damage owing to an arterial irrigation defect
11/14/2002	WO2002049634A3 Dissociated glucocorticoid receptor antagonists for the treatment of clucocorticoid associated side-effect
11/14/2002	WO2002038534A3 Substituted alkyldiamines as inhibitors of plasmepsin or related proteases
11/14/2002	WO2002028906A3 Regulation of human sphingosine kinase-like protein
11/14/2002	WO2002018623A3 Methods and reagents for protease inhibition
11/14/2002	WO2002018404A3 Nucleoside derivatives for the treatment of hepatitis c
11/14/2002	WO2002007713A3 Medicaments containing cilansetron for treating non-obstipated male ibs patients
11/14/2002	WO2001097787A3 Use of microsomal triglyceride transfer protein (mtp) inhibitors for reducing the number of postprandial triglyceride-rich lipoprotein particles (pptrl)
11/14/2002	WO2001035106A3 Methods for identifying and using amyloid-inhibitory compounds
11/14/2002	WO2001007030A3 Compositions an inhibitor of an accrab-like efflux pump for reducung microbial resistance to drugs
11/14/2002	US20020169336 Able to inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders
11/14/2002	US20020169326 Fatty acid derivatives
11/14/2002	US20020169322 Use of N-alkylamino-heterocylic compounds for the treatment of migraine
11/14/2002	US20020169317 Oxazinocarbazoles for the treatment of CNS diseases
11/14/2002	US20020169301 Nucleotide sequences coding polypeptide for use in the diagnosis and treatment of cell proliferative disorders
11/14/2002	US20020169291 Interleukin-18 mutants, their production and use
11/14/2002	US20020169215 Treatment of a disease that is mediated by the expression or suppression of a redox sensitive gene, for example MCP-1, IL-6 and thrombin receptor; antiinflammatory agents; cardio-vascular disorders; atherosclerosis; immunology
11/14/2002	US20020169209 Potentiation of therapeutic effects of fatty acids
11/14/2002	US20020169208 Oxybutynin analogs; antichloinergic agents; side effect reduction; short half-life; water-soluble metabolites; incontinence; mydriatic and bronchodilator agents; respiratory system disorders; antiperspirants
11/14/2002	US20020169203 Modulators of all three classes of calcium channel blocker subtypes (Small, Intermediate and Big conductance K channel (SK, IK and BK)) comprising malonate esters and nitriles; respiratory, brain, cardiovascular, urogenital disorders
11/14/2002	US20020169202 Promoter for production of nitric oxide or nitric oxide synthase, and cosmetic or pharmaceutical composition comprising the same
11/14/2002	US20020169200 Antitumor, antiinflammatory and antiarthritic agents, treating metastasis, restenosis, osteoporosis, inflammation, macular degeneration, and diabetic retinopathy
11/14/2002	US20020169198 Agonists of the progesterone receptor; contraceptives, hormone replacement therapy and treating menopause symptoms
11/14/2002	US20020169192 Peroxisome proliferator activator receptor (PPAR); amino-ethyl- phenyl derivatives
11/14/2002	US20020169189 Benzamide derivatives as thrombin inhibitors
11/14/2002	US20020169186 Tetrahydroquinoline derivatives as glycine antagonists
11/14/2002	US20020169178 Benzothieno[3,2-c]pyridines as alpha2 antagonists
11/14/2002	US20020169177 Imidazole and benzimidazole caspase inhibitors and uses thereof
11/14/2002	US20020169174 Xanthine phosphodiesterase V inhibitors
11/14/2002	US20020169171 Alkoxycarbonylamino heteroaryl carboxylic acid derivatives as IP antagonists
11/14/2002	US20020169170 Arylpiperazines having activity at the serotonin 1A receptor
11/14/2002	US20020169169 5-aminoalkyl and 5-aminocarbonyl substituted indole derivative useful for treatment of psychosis in a mammal
11/14/2002	US20020169165 Substituted bicyclic derivatives for the treatment of abnormal cell growth
11/14/2002	US20020169164 Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases
11/14/2002	US20020169163 1,2,3,4-tetrahydro-pyrazino(1,2-a)indole derivatives useful in treating obesity, central nerveous system diosrders, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, type II diabetes, obesity and sleep apnoea
11/14/2002	US20020169160 Sulfonamide matrix metalloproteinase inhibitors
11/14/2002	US20020169159 An acetamide derivative is useful for treatment of inflammatory and immune conditions and diseases; modulates the expressin and/or function of a chemokine receptor
11/14/2002	US20020169156 Azacyclooctane and heptane derivatives, their preparation and use in therapy
11/14/2002	US20020169152 Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
11/14/2002	US20020169150 Hormone replacement therapy
11/14/2002	US20020169134 Use of substituted azetidinone compounds for the treatment of sitosterolemia
11/14/2002	US20020169133 Treatment of diseases characterized by excessive deposits of fibrillar interstitial collagens that are resistant to proteolyic degradation thus leading to symptoms of fibrosis
11/14/2002	US20020169131 TGF-alpha polypeptides, functional fragments and methods of use therefor
11/14/2002	US20020169114 Formulation of boronic acid compounds
11/14/2002	US20020169109 Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin
11/14/2002	US20020169103 Novel treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
11/14/2002	US20020168754 Nucleotide sequences coding polypeptides for use in the treatment of gastric, testicular, retinal, nervous system and immunological disorders
11/14/2002	US20020168753 In vitro formation of congophilic maltese-cross amyloid plaques to identify anti-plaque therapeutics for the treatment of Alzheimer's and Prion diseases
11/14/2002	US20020168740 Kinase for use in the treatment of inflammation, viral infection, cancer, sepsis, psoriasis and restenosis
11/14/2002	US20020168716 Nucleotide sequences coding polypeptide for use in the treatment and diagnosis of tumors, immunological, autoimmune, skin, viral, bone, nervous system and inflammatory disorders
11/14/2002	US20020168710 Anticancer agents; cardiovascular disorders; anticholesterol agents
11/14/2002	US20020168434 Cyclooxygenase inhibitor; anticancer agents, Alzheimer's disease, central nervous system disorders
11/14/2002	US20020168411 Spill resistant pharmaceutical system
11/14/2002	US20020168389 Oil in water emulsion; skin disorders
11/14/2002	US20020168388 Topical cosmetic composition
11/14/2002	US20020168383 Modifications of antigens by the introduction of aldehyde groups and their use in enhancing the immune response
11/14/2002	US20020168381 Mixture of bone protein and ethylene oxide-propylene oxide copolymer; in situ administering
11/14/2002	US20020168380 Moderating immunology response
11/14/2002	US20020168374 Hla binding peptides and their uses
11/14/2002	US20020168360 Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphanubeta3 antagonists in combination with other prophylactic or therapeutic agents
11/14/2002	US20020168358 Modulating the binding of the particular chemokines SLC (secondary lymphoid chemokine), and MIP-3b (macrophage inflammatory protein-3b), to immune system T-cells and dendritic cells to treat adverse inflammatory responses etc
11/14/2002	US20020168338 Compositions and methods for delivery of agents for neuronal regeneration and survival
11/14/2002	US20020168325 Administering inhibitor of nitric oxide synthase
11/14/2002	DE10121982A1 Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung Nanoparticles of protein with coupled apolipoprotein E to cross the blood-brain barrier and method for their preparation
11/14/2002	DE10119680A1 Verwendung von Radikalfänger-Verbindungen zur Behandlung und Verhinderung von no-abhängigen Störungen der Mikrozirkulation Use of scavenger compounds for the treatment and prevention of no-dependent disorders of microcirculation
11/14/2002	DE10116829A1 Neuropeptid bindende Nukleinsäuren Neuropeptide binding nucleic acids
11/14/2002	CA2453223A1 Selective anthranilamide pyridinamides as vegfr-2 and vegfr-3 inhibitors
11/14/2002	CA2452245A1 Recombinant fusion proteins and the trimers thereof
11/14/2002	CA2449166A1 Combination therapy using anti-egfr antibodies and anti-hormonal agents
11/14/2002	CA2447360A1 Pharmaceutical compositions for preventing or treating th1 and th2 cell related diseases by modulating the th1/th2 ratio.
11/14/2002	CA2447045A1 Method for treatment of tumors using nordihydroguaiaretic acid derivatives
11/14/2002	CA2446810A1 Epidermal growth factor receptorantisense oligonucleotides

1 ... 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 ... 1564